Centene Corporation vs Elevance Health, Inc.: Strategic Comparison

This in-depth comparison examines Centene Corporation and Elevance Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Centene Corporation on its own, evaluating Elevance Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Centene Corporation and Elevance Health, Inc. is widest.

On the headline numbers, Centene Corporation reports annual revenue of $194.8B against $199.1B for Elevance Health, Inc., while their respective market capitalizations stand at $30.5B and $80.0B. Centene Corporation is headquartered in United States and Elevance Health, Inc. operates from United States, and those different home markets shape how each company competes.

Centene Corporation: Centene is a Fortune 500 healthcare company that runs a large share of America's government-funded health coverage. Unlike insurers built on employer plans, it focuses on Medicaid, the ACA Marketplace through its Ambetter brand, and Medicare through Wellcare. Headquartered in St. Louis, Missouri, it is the largest Medicaid managed care organization in the U.S., serving about 12.1 million Medicaid members, 3.5 million Marketplace members and 8.8 million Medicare Part D members as of June 30, 2026.

Elevance Health, Inc.: Elevance Health is one of the largest U.S. health insurers by revenue, with roughly 45 million medical members and about 104 million consumers served across its businesses. It sells Anthem Blue Cross and Blue Shield plans in 14 states, Wellpoint government plans in others, and pharmacy and health services through Carelon.

Centene Corporation and Elevance Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Centene Corporation and Elevance Health, Inc..

Centene Corporation business model: Centene earns most of its money from premiums paid by governments. State Medicaid agencies pay it a fixed monthly amount per enrolled member to manage that member's care; the federal Centers for Medicare & Medicaid Services (CMS) pays it for Medicare Advantage and Part D drug plans; and ACA Marketplace members pay Ambetter premiums that are largely funded by federal tax credits. Centene then contracts with doctors, hospitals and pharmacies and profits only if total medical costs plus administrative expenses come in below those premiums. That spread is thin: in Q2 2026 its health benefits ratio was 89.6% and its SG&A ratio 7.0%, so small swings in medical use or rates move earnings sharply.

Elevance Health, Inc. business model: Elevance makes money in two ways. First, its Health Benefits segment collects premiums from employers, individuals and government programs and pays members' medical claims; profit depends on keeping the benefit expense ratio (89.7% in Q2 2026) below premium levels and on fees for administering self-funded employer plans. Second, Carelon earns pharmacy and services revenue: CarelonRx manages prescription benefits and dispenses specialty drugs, while Carelon Services sells behavioral health, home-based care and risk-based care management, increasingly to outside health plans as well as Elevance's own members. Carelon produced $19.2B of operating revenue and $0.9B of operating gain in Q2 2026.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Centene Corporation stack up against those of Elevance Health, Inc..

Centene Corporation competitive advantage: Centene's main advantage is scale and experience in state Medicaid programs. It serves about 12.1 million Medicaid members across 30 states, and every state runs its own procurement, rate-setting and compliance rules. Winning and keeping those contracts requires local provider networks, quality reporting and regulatory relationships built over decades, which makes it hard for new entrants to compete for large state awards.

Elevance Health, Inc. competitive advantage: Elevance's main edge is its Blue Cross Blue Shield licenses in 14 states, which give it dense local provider networks and strong brand recognition with employers, plus access to the national BlueCard network. Owning CarelonRx and Carelon Services lets it keep pharmacy and care-management revenue that rivals without those assets pay to third parties.

Future prospects matter as much as current results. The growth strategies below explain how Centene Corporation and Elevance Health, Inc. each plan to expand from here.

Centene Corporation growth strategy: Under CEO Sarah London, who succeeded Michael Neidorff in 2022, Centene has narrowed its focus to U.S. government-sponsored health plans. It sold non-core assets such as Magellan Rx, its Spanish hospital operator Ribera Salud and UK-based Circle Health, outsourced pharmacy benefit management to Express Scripts, and cut administrative costs. Growth now centers on repricing Marketplace plans for profitability, expanding Medicare Part D (8.8 million PDP members at June 30, 2026), dual-eligible Medicaid-Medicare plans, and improving Medicare Advantage Star Ratings.

Elevance Health, Inc. growth strategy: Elevance is pruning lower-margin business, such as exiting standalone Medicare Part D plans for 2026 and the D.C. Medicaid market, while investing in medical cost management, provider connectivity and Carelon. Recent deals that extend Carelon include BioPlus specialty pharmacy (2023), Kroger Specialty Pharmacy (2024) and CareBridge home-based care (reported at about $2.7B, 2024 to 2025).

A closer look at the financial trajectory of Centene Corporation and Elevance Health, Inc. rounds out the comparison.

Centene Corporation: Centene's revenue grew from $144.5 billion in 2022 to $194.8 billion in 2025, but profit moved the other way. FY2025 ended with a $6.674 billion GAAP net loss attributable to Centene, compared with $3.3 billion of net income in 2024, after a $6.7 billion non-cash goodwill impairment recorded in Q3 2025; adjusted diluted EPS was $2.08. The turnaround showed up in 2026: Q2 2026 total revenue was $53.6 billion, premium and service revenue was $44.4 billion, GAAP diluted EPS was $2.19 and adjusted diluted EPS was $2.51. Centene raised its 2026 guidance to GAAP diluted EPS above $3.11 and adjusted diluted EPS above $4.80, with premium and service revenue guided to $173-$177 billion. The company does not pay a dividend.

Elevance Health, Inc.: Revenue rose from $171.3B in 2023 to $177.0B in 2024 and $199.1B in 2025, helped by premium-rate increases, acquisitions and Medicare Advantage growth that offset Medicaid attrition. Net income was $5.662B in 2025 on operating income of $7.199B. Growth slowed in 2026 as the company deliberately shrank unprofitable Medicaid, Medicare Advantage and employer risk business: operating revenue was $49.5B in Q1 2026 and $49.8B in Q2 2026. In July 2026 Elevance raised full-year guidance to at least $20.10 GAAP diluted EPS and at least $27.00 adjusted EPS, with operating cash flow of at least $6.0B, and paid a $1.72 quarterly dividend.